アルツハイマー病治療薬のグローバル市場:産業動向、シェア、規模、成長、機会・予測(2022~2027)

【英語タイトル】Alzheimer’s Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

IMARCが出版した調査資料(IMARC22DV0022)・商品コード:IMARC22DV0022
・発行会社(調査会社):IMARC
・発行日:2022年10月
・ページ数:140
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single UserUSD2,499 ⇒換算¥369,852見積依頼/購入/質問フォーム
Five UserUSD3,499 ⇒換算¥517,852見積依頼/購入/質問フォーム
EnterprisewideUSD4,499 ⇒換算¥665,852見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

IMARC社は、2021年68億ドルであった世界のアルツハイマー病治療薬市場規模が2027年には98億ドルに達し、予測期間中、年平均6.21%成長すると予測しています。本調査レポートでは、アルツハイマー病治療薬の世界市場を調査・分析し、序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、医薬品クラス別(ドネペジル、ガランタミン、リバスチグミン、メマンチン、その他)分析、流通チャネル別(病院薬局、小売薬局、オンライン、その他)分析、地域別(北米、アジア太平洋、ヨーロッパ、中南米、中東・アフリカ)分析、SWOT分析、バリューチェーン分析、ファイブフォース分析、価格分析、競争状況などの項目を掲載しています。また、こちらの調査レポートに掲載されている企業情報には、Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly,Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc,Teva Pharmaceutical Industries Limitedなどが含まれています。
・序論
・範囲・調査手法
・エグゼクティブサマリー
・イントロダクション
・世界のアルツハイマー病治療薬市場規模:医薬品クラス別
- ドネペジルの市場規模
- ガランタミンの市場規模
- リバスチグミンの市場規模
- メマンチンの市場規模
- その他アルツハイマー病治療薬の市場規模
・世界のアルツハイマー病治療薬市場規模:流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンラインチャネルの市場規模
- その他チャネルの市場規模
・世界のアルツハイマー病治療薬市場規模:地域別
- 北米のアルツハイマー病治療薬市場規模
- アジア太平洋のアルツハイマー病治療薬市場規模
- ヨーロッパのアルツハイマー病治療薬市場規模
- 中南米のアルツハイマー病治療薬市場規模
- 中東・アフリカのアルツハイマー病治療薬市場規模
・SWOT分析
・バリューチェーン分析
・ファイブフォース分析
・価格分析
・競争状況

The global alzheimer’s drugs market size reached US$ 6.8 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 9.8 Billion by 2027, exhibiting a growth rate (CAGR) of 6.21% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Alzheimer’s is a disease characterized by the degeneration of nerve cells in several areas of the brain. It causes loss of cognitive function, such as memory, language, thinking and behavior. The common symptoms of Alzheimer’s include depression, memory impairment, loss of inhibitions, and problems with thinking and reasoning. It is usually diagnosed by performing physical exams, blood tests, brain imaging, and mental status and neuropsychological testing. According to the results, doctors prescribe different medications to alleviate symptoms. Alzheimer’s drugs influence the functions of neurotransmitters, the chemicals involved in carrying messages between nerve cells in the brain.

Alzheimer’s Drugs Market Trends:
Diabetes, obesity, heart diseases and high blood pressure (BP), in confluence with sedentary lifestyles, unhealthy dietary patterns and smoking, are some of the factors known to increase the chances of developing Alzheimer’s disease. An increase in the prevalence of these ailments and lifestyle choices among the masses, coupled with the rising geriatric population, represents one of the key factors driving the market growth. Furthermore, the leading pharmaceutical companies are focusing on the development of drugs that prevent the disease and provide long-lasting improvements in cognitive functions. The market growth is further supported by the expansion of telehealth services and the growing traction of online pharmacies. These platforms have enabled disease diagnosis and drug delivery in remote regions. Apart from this, various Alzheimer’s drugs are presently under late-stage clinical trials, including Aducanumab, Solanezumab and Insulin.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global alzheimer’s drugs market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

Donepezil
Galantamine
Rivastigmine
Memantine
Others

Breakup by Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Stores
Others

Breakup by Region:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited.

Key Questions Answered in This Report:
How has the global alzheimer’s drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global alzheimer’s drugs market?
What are the key regional markets?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global alzheimer’s drugs market and who are the key players?
What is the degree of competition in the industry?

❖ レポートの目次 ❖

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Alzheimer’s Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 Donepezil
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Galantamine
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Rivastigmine
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Memantine
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Distribution Channel
7.1 Hospital Pharmacy
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Retail Pharmacy
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Online Stores
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Abbvie Inc.
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 AstraZeneca PLC
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 Biogen Inc.
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.3.4 SWOT Analysis
13.3.4 Daiichi Sankyo Company Limited
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 Eisai Co. Ltd.
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 Financials
13.3.5.4 SWOT Analysis
13.3.6 Eli Lilly and Company
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 H. Lundbeck A/S
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 F. Hoffmann-La Roche AG
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 SWOT Analysis
13.3.9 Merck & Co. Inc.
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.9.4 SWOT Analysis
13.3.10 Novartis AG
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.10.3 Financials
13.3.10.4 SWOT Analysis
13.3.11 Ono Pharmaceutical Co. Ltd.
13.3.11.1 Company Overview
13.3.11.2 Product Portfolio
13.3.11.3 Financials
13.3.11.4 SWOT Analysis
13.3.12 Pfizer Inc.
13.3.12.1 Company Overview
13.3.12.2 Product Portfolio
13.3.12.3 Financials
13.3.12.4 SWOT Analysis
13.3.13 Teva Pharmaceutical Industries Limited
13.3.13.1 Company Overview
13.3.13.2 Product Portfolio
13.3.13.3 Financials
13.3.13.4 SWOT Analysis

Figure 1: Global: Alzheimer’s Drugs Market: Major Drivers and Challenges
Figure 2: Global: Alzheimer’s Drugs Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Alzheimer’s Drugs Market: Breakup by Drug Class (in %), 2021
Figure 4: Global: Alzheimer’s Drugs Market: Breakup by Distribution Channel (in %), 2021
Figure 5: Global: Alzheimer’s Drugs Market: Breakup by Region (in %), 2021
Figure 6: Global: Alzheimer’s Drugs Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 7: Global: Alzheimer’s Drugs (Donepezil) Market: Sales Value (in Million US$), 2016 & 2021
Figure 8: Global: Alzheimer’s Drugs (Donepezil) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 9: Global: Alzheimer’s Drugs (Galantamine) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Alzheimer’s Drugs (Galantamine) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Alzheimer’s Drugs (Rivastigmine) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Alzheimer’s Drugs (Rivastigmine) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Alzheimer’s Drugs (Memantine) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Alzheimer’s Drugs (Memantine) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Alzheimer’s Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Alzheimer’s Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Alzheimer’s Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Alzheimer’s Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Alzheimer’s Drugs (Retail Pharmacy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Alzheimer’s Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Alzheimer’s Drugs (Online Stores) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Alzheimer’s Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Alzheimer’s Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Alzheimer’s Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: North America: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: North America: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: United States: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: United States: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Canada: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Canada: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Asia Pacific: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: Asia Pacific: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: China: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: China: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Japan: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Japan: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: India: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: India: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: South Korea: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: South Korea: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: Australia: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: Australia: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: Indonesia: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: Indonesia: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: Others: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: Others: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: Europe: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: Europe: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: Germany: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: Germany: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: France: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: France: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: United Kingdom: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: United Kingdom: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: Italy: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: Italy: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: Spain: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: Spain: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: Russia: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: Russia: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: Others: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: Others: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Latin America: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Latin America: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Brazil: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Brazil: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Mexico: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: Mexico: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: Others: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: Others: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Middle East and Africa: Alzheimer’s Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 72: Middle East and Africa: Alzheimer’s Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: Global: Alzheimer’s Drugs Industry: SWOT Analysis
Figure 74: Global: Alzheimer’s Drugs Industry: Value Chain Analysis
Figure 75: Global: Alzheimer’s Drugs Industry: Porter’s Five Forces Analysis

★調査レポート[アルツハイマー病治療薬のグローバル市場:産業動向、シェア、規模、成長、機会・予測(2022~2027)] (コード:IMARC22DV0022)販売に関する免責事項を必ずご確認ください。
★調査レポート[アルツハイマー病治療薬のグローバル市場:産業動向、シェア、規模、成長、機会・予測(2022~2027)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆